http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11352350

Outgoing Links

Predicate Object
contentType Journal Article
issn 2234-943X
pageRange 52-
publicationName Frontiers in Oncology
startingPage 52
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_34ca8174f0b8284aa80e1059fd7e37d8
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577
bibliographicCitation Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol. 2011;1():52. PMID: 22649768; PMCID: PMC3355954.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da5ae3347309f048290fd131f788aa26
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c20d52e84b596e5c6f24fb9ca2a11b3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b4ed3de3738c7e014e51515a28137f9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b1f7ff44c5d06b42e1ba79dab1123086
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_104f080d67659197a0a921988f1746bc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f776f2b6e119445a32880a5f1964ec1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d502d45dfd0df4270c5f9cbe8c3c6fc2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd67360aa629663be36facfa80a159aa
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d56693f8b2875cbcf93da12a35552426
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d0b84508c6bbab29ec3d5e151cc37cbd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e6c8b7aa18c8577927e9a8e58d8aca0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bdc7c1d8a5af9fb302efc979a5215c8
date 2011
identifier https://pubmed.ncbi.nlm.nih.gov/PMC3355954
https://doi.org/10.3389/fonc.2011.00052
https://pubmed.ncbi.nlm.nih.gov/22649768
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39509
https://portal.issn.org/resource/ISSN/2234-943X
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9025
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_25e7482d087cb6429609f07a507aa159
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2662
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7655
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7654

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127822827
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128288519
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129202881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127638306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135867281
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129203714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127838534
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136123131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135935854
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243681044
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128236891
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128121087

Total number of triples: 66.